{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:52:53Z","timestamp":1788349973260,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd."},{"DOI":"10.13039\/100019271","name":"Kyorin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13318-025-00977-w","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:47:51Z","timestamp":1770288471000},"page":"179-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bioequivalence and Comparative Pharmacokinetics of Two Generic Mirogabalin Besylate Tablets (5 mg and 10 mg) and Tarlige\u00ae in Healthy Chinese Volunteers: A Pooled Analysis of Two Randomized, Open-Label, Two-Period Crossover Studies"],"prefix":"10.1007","volume":"51","author":[{"given":"Fengling","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolian","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"977_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.813210","volume":"12","author":"J Lian","year":"2021","unstructured":"Lian J, Wang H, Cui R, Zhang C, Fu J. Status of analgesic drugs and quality of life results for diabetic peripheral neuropathy in China. Front Endocrinol. 2021;12:813210.","journal-title":"Front Endocrinol"},{"issue":"4","key":"977_CR2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-019-01070-8","volume":"79","author":"ED Deeks","year":"2019","unstructured":"Deeks ED. Mirogabalin: first global approval. Drugs. 2019;79(4):463\u20138.","journal-title":"Drugs"},{"key":"977_CR3","unstructured":"Daiichi Sankyo Company. Tarlige\u00aeTablets: Prescribing Information. 2019. Available online: http:\/\/www.info.pmda.go.jp\/downf. Accessed on 15 April 2024."},{"key":"977_CR4","unstructured":"Center for Drug Evaluation of NMPA (2023). Mirogabalin besylate for listing in China. https:\/\/english.nmpa.gov.cn\/2019-07\/19\/c_389169.html. Accessed 3 Sept 2024."},{"issue":"5","key":"977_CR5","first-page":"496","volume":"16","author":"Branch Group of Neurological Complications, Chinese Diabetes Society, National Office of Basic Public Health Service Program for Primary Diabetes Care","year":"2024","unstructured":"Branch Group of Neurological Complications, Chinese Diabetes Society, National Office of Basic Public Health Service Program for Primary Diabetes Care. National guidelines for the diagnosis and treatment of diabetic neuropathy in primary care (2024 edition). Chin J Diabetes Mellit. 2024;16(5):496\u2013511.","journal-title":"Chin J Diabetes Mellit"},{"issue":"5","key":"977_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.418","volume":"6","author":"K Brown","year":"2018","unstructured":"Brown K, Mendell J, Ohwada S, Hsu C, He L, Warren V, et\u00a0al. Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: results from phase 1 studies. Pharmacol Res Perspect. 2018;6(5):e00418.","journal-title":"Pharmacol Res Perspect"},{"issue":"11","key":"977_CR7","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s40261-018-0692-7","volume":"38","author":"K Duchin","year":"2018","unstructured":"Duchin K, Senaldi G, Warren V, Marbury T, Lasseter K, Zahir H. Open-label single-dose study to assess the effect of mild and moderate hepatic impairment on the pharmacokinetics of mirogabalin. Clin Drug Investig. 2018;38(11):1001\u20139.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"977_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/00498254.2021.1879408","volume":"51","author":"N Yamamura","year":"2021","unstructured":"Yamamura N, Mendel-Harary J, Brown K, Uchiyama M, Urasaki Y, Takahashi M, et\u00a0al. Metabolism, excretion, and pharmacokinetics of [14C]mirogabalin, a novel \u03b12\u03b4 ligand, in healthy volunteers following oral administration. Xenobiotica. 2021;51(5):549\u201363.","journal-title":"Xenobiotica"},{"issue":"1","key":"977_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/jcph.974","volume":"58","author":"M Kato","year":"2018","unstructured":"Kato M, Tajima N, Shimizu T, Sugihara M, Furihata K, Harada K, et\u00a0al. Pharmacokinetics and safety of a single oral dose of mirogabalin in Japanese subjects with varying degrees of renal impairment. J Clin Pharmacol. 2018;58(1):57\u201363.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"977_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/jcph.584","volume":"56","author":"OQP Yin","year":"2016","unstructured":"Yin OQP, Merante D, Truitt K, Miller R. Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin. J Clin Pharmacol. 2016;56(2):203\u201312.","journal-title":"J Clin Pharmacol"},{"key":"977_CR11","unstructured":"China Food and Drug Administration (CFDA). Technical guiding principles for research on human bioequivalence of chemical drug generic drugs with pharmacokinetic parameters as endpoint evaluation index. Center for Drug Evaluation (CDE); 2016. https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=1e218f70d9b7c99c2663de9f6655bc5b. Accessed 20 July 2025."},{"issue":"10","key":"977_CR12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/cpdd.1292","volume":"12","author":"K Toyama","year":"2023","unstructured":"Toyama K, Eto T, Suzuki K, Shinohara S, Yoshiba S, Yoshihara K, et\u00a0al. Pharmacokinetics and bioequivalence of mirogabalin orally disintegrating tablets and conventional tablets in healthy Japanese participants. Clin Pharmacol Drug Dev. 2023;12(10):985\u201390.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"977_CR13","unstructured":"Daiichi Sankyo Co., Ltd. TARLIGE\u00ae (mirogabalin besylate) tablets: Japanese prescribing information (version: May 2023). Tokyo, Japan; 2023."},{"issue":"4","key":"977_CR14","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1007\/s12325-022-02424-7","volume":"40","author":"Y Li","year":"2023","unstructured":"Li Y, Toyama K, Nakatsu T, Ishizuka H, Wu H, Cao G, et\u00a0al. Safety, tolerability and pharmacokinetics of single and multiple doses of mirogabalin in healthy Chinese participants: a randomized, double-blind, placebo-controlled study. Adv Ther. 2023;40(4):1628\u201343.","journal-title":"Adv Ther"},{"issue":"20","key":"977_CR15","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Med Assoc. 2013;310(20):2191\u20134.","journal-title":"J Am Med Assoc"},{"key":"977_CR16","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Integrated Addendum to ICH E6(R1): guideline for good clinical practice E6(R2). 2016. https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf. Accessed 24 Jan 2025."},{"key":"977_CR17","unstructured":"US Food and Drug Administration. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Center for Drug Evaluation and Research (CDER); 2022. https:\/\/www.fda.gov\/media\/70858\/download. Accessed 22 Jan 2025."},{"key":"977_CR18","unstructured":"National Medical Products Administration (NMPA). Guideline for Statistical Approaches to Bioequivalence Studies. Center for Drug Evaluation (CDE); 2018. https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=04af995337832a507fe27bde66f03eda. Accessed 20 July 2025."},{"issue":"4","key":"977_CR19","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s40122-025-00732-8","volume":"14","author":"T Nikaido","year":"2025","unstructured":"Nikaido T, Tabata S, Shiosakai K, Nakatani T, Sakoda H. Safety and efficacy of mirogabalin in lumbar spinal stenosis patients with peripheral neuropathic pain on NSAIDs: post hoc analysis of the MiroTAS study. Pain Ther. 2025;14(4):1293\u2013310.","journal-title":"Pain Ther"},{"issue":"6","key":"977_CR20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/cpdd.448","volume":"7","author":"M Jansen","year":"2018","unstructured":"Jansen M, Warrington S, Dishy V, Ohwada S, Johnson L, Brown K, et\u00a0al. A randomized, placebo-controlled, double-blind study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and repeated doses of mirogabalin in healthy Asian volunteers. Clin Pharmacol Drug Dev. 2018;7(6):661\u20139.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"977_CR21","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.clinthera.2021.03.015","volume":"43","author":"J Kato","year":"2021","unstructured":"Kato J, Baba M, Kuroha M, Kakehi Y, Murayama E, Wasaki Y, et\u00a0al. Safety and efficacy of mirogabalin for peripheral neuropathic pain: pooled analysis of two pivotal phase III studies. Clin Ther. 2021;43(5):822-835.e16.","journal-title":"Clin Ther"},{"issue":"2","key":"977_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13492","volume":"16","author":"C Jin","year":"2024","unstructured":"Jin C, Lai Y, Li Y, Teng D, Yang W, Teng W, et\u00a0al. Changes in the prevalence of diabetes and control of risk factors for diabetes among Chinese adults from 2007 to 2017: an analysis of repeated national cross-sectional surveys. J Diabetes. 2024;16(2):e13492.","journal-title":"J Diabetes"},{"key":"977_CR23","unstructured":"US Food and Drug Administration. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. Center for Drug Evaluation and Research (CDER); 2021. https:\/\/www.fda.gov\/media\/87219\/download. Accessed 20 Jan 2025."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00977-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00977-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00977-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:23:52Z","timestamp":1774625032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00977-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["977"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00977-w","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"23 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) report no conflicts of interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All participants provided written, signed, and dated informed consent prior to any study-related procedures, in compliance with Good Clinical Practice and Chinese regulatory requirements. Participants were thoroughly informed about the study objectives, procedures, potential risks, and benefits before consenting.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All procedures performed in these studies were reviewed and approved by the Clinical Trial Ethics Committee of The Second People\u2019s Hospital of Hefei (approval no. 2023 Ethical Opinion-Medical-020-01 for the 5 mg study; approval no. 2024 Ethical Opinion-Medical-026-01 for the 10 mg study). The studies were conducted in accordance with the ethical principles originating from the Declaration of Helsinki and consistent with Good Clinical Practice and applicable regulatory requirements.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Original data supporting the conclusions of this study will be provided by the corresponding author (Xiangyun Meng) and should be retained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The study was conceived and designed by XYM, FLW, HTY, and CHL. XYM, FLW, XY, FL, and AGW conducted the research and acquired data. FLW and XY drafted the manuscript; LYW, XLX, LLZ, and LMZ performed data review, result analysis, and clinical trial report preparation. All authors critically reviewed the intellectual content, provided substantive revisions, and granted final approval for submission.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}